Position in AYTU
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$420
+$293 QoQ
Shares Held
154
+105.3% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AYTU Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026JPMORGAN CHASE & CO holds $2,053,486,048 across 61 Drug Manufacturers - Specialty & Generic names. AYTU ranks #55 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
5,442,067 | $716,937,900 | |
| 2 | ZTS |
Zoetis Inc.
|
3,387,174 | $400,397,831 | |
| 3 | TEVA |
Teva Pharmaceutical Industries Ltd
|
6,762,744 | $203,693,847 | |
| 4 | ALKS |
Alkermes plc.
|
4,101,789 | $145,039,257 | |
| 5 | HIMS |
Hims & Hers Health, Inc.
|
5,240,816 | $108,799,337 | |
| 6 | HLN |
Haleon plc
|
8,279,468 | $82,877,469 | |
| 7 | VTRS |
Viatris Inc
|
5,731,565 | $77,433,437 | |
| 8 | RDY |
Dr Reddys Laboratories Ltd
|
4,371,378 | $60,543,580 |
All Filings in AYTU
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $420 | 154 | Shares | Defined | 2026-05-13 | |
| 2024-12-31 | $127 | 75 | Shares | Defined | 2025-02-12 | |
| 2024-09-30 | $735 | 313 | Shares | Defined | 2024-12-26 | |
| 2024-06-30 | $1,576 | 540 | Shares | Defined | 2024-12-26 | |
| 2024-03-31 | $1,884 | 620 | Shares | Defined | 2024-12-26 | |
| 2023-12-31 | $19,411 | 6,835 | Shares | Defined | 2024-12-26 | |
| 2023-09-30 | $5,907 | 2,188 | Shares | Defined | 2023-11-14 | |
| 2023-06-30 | $939 | 587 | Shares | Defined | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||